Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Dementia01:30

Dementia

609
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
609
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

649
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
649
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.6K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.7K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.7K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

531
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
531

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Barriers and facilitators to intracerebral haemorrhage platform trial recruitment: a survey of stroke clinicians.

Cerebrovascular diseases (Basel, Switzerland)·2026
Same author

Rates, risks and routes to reduce vascular dementia (R4VaD), a UK-wide multicentre prospective observational cohort study of cognition after stroke: baseline data and statistical analysis plan (ISRCTN18274006).

Cerebrovascular diseases extra·2026
Same author

Effect of tranexamic acid for acute spontaneous intracerebral haemorrhage: a systematic review and individual patient data meta-analysis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled Trial.

Stroke·2026
Same author

Early versus delayed anticoagulation in acute ischemic stroke with atrial fibrillation according to infarct volume and location: A prespecified subgroup analysis of the OPTIMAS randomized controlled trial.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Biomarkers for advancing diagnosis and prognosis in stroke.

The Lancet. Neurology·2026

Related Experiment Video

Updated: Feb 27, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K

Hypercholesterolaemia and vascular dementia.

Jason P Appleton1, Polly Scutt1, Nikola Sprigg1

  • 1Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham NG5 1PB, U.K.

Clinical Science (London, England : 1979)
|July 2, 2017
PubMed
Summary

Vascular dementia (VaD) is a common condition linked to stroke and vascular risk factors. Current evidence does not support lipid-lowering therapy for preventing or treating VaD.

Keywords:
cholesterolcognitive impairmenthypercholesterolaemiastatinsvascular dementia

More Related Videos

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.7K
Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice
04:29

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice

Published on: May 17, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 27, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.7K
Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice
04:29

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice

Published on: May 17, 2024

1.2K

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Geriatrics

Background:

  • Vascular dementia (VaD) is the second leading cause of dementia globally.
  • Stroke is a major cause of disability, dementia, and mortality.
  • Vascular risk factors like hypertension, diabetes, and smoking are implicated in VaD.

Purpose of the Study:

  • To review the complex associations between cholesterol, small vessel disease, stroke, and cognitive impairment.
  • To evaluate the efficacy of lipid-lowering therapy in preventing or treating dementia.
  • To discuss the implications for clinical practice and future research.

Main Methods:

  • Literature review of studies on vascular dementia, stroke, and lipid management.
  • Analysis of existing randomized controlled trials on lipid-lowering therapy for dementia.
  • Synthesis of evidence regarding vascular risk factors and cognitive decline.

Main Results:

  • The relationship between cholesterol, small vessel disease, stroke, and cognitive impairment is not fully understood.
  • Few trials assessing lipid-lowering therapy for dementia prevention or treatment found no supporting evidence.
  • Managing vascular risk factors according to guidelines is recommended for cardiovascular and cerebrovascular event prevention.

Conclusions:

  • Current evidence does not support using lipid-lowering therapy specifically for dementia prevention or treatment.
  • Holistic patient management based on individual vascular risk profiles is advised.
  • Limited randomized controlled evidence highlights the need for further research in this area.